Skip to main content

Advertisement

SpringerLink
Log in

Understanding the reasons for delayed referral for intrathecal baclofen therapy in pediatric patients with severe spasticity

  • Original Paper
  • Published:
Child's Nervous System Aims and scope Submit manuscript

Abstract

Objective

Intrathecal baclofen therapy (ITB) has been used in the treatment of spasticity and dystonia. In our pediatric movement disorder clinic, we noted a delay in referral of patients for consideration of ITB. Often, only after years of failed medical therapy, a baclofen pump is considered. This study attempts to investigate the prevalence, length and causes of the delay.

Methods

A retrospective, outcome analysis was performed. We conducted a survey of 30 pediatric patients who received baclofen pumps between the ages of 5 and 23. Patients were divided into two groups (before and after ITB approval by the US Food and Drug Administration in 1996) (FDA/Center for Drug Evaluation and Research, 2014; Ridley and Rawlins, J Neurosci Nurs 38:72–82, 2006; Medical Advisory Secretariat, Ont Health Technol Assess Ser 5:1–93, 2005). Information was collected regarding their onset of spasticity, attempted treatments, pump referral, satisfaction, and resulting change in the quality of life.

Results

There was a delay in referral in most cases investigated. Average time to baclofen pump implantation, after initial onset of spasticity, was 5.14 years (group A) and 11.7 years (group B). Out of the subjects who reported diminished effects or no effect of pharmacological treatment, 93 % of these respondents reported that ITB had a dramatic long-lasting effect on their spasticity. Of 30 patients, 28 reported effectiveness of ITB, and 26 of 30 subjects reported an improved quality and ease of life.

Conclusion

Despite the limitations of this subjective retrospective analysis of outcomes and delay in referral, the opinions of the parents and caregivers should be considered. Earlier referral for ITB therapy may better treat severe spasticity in pediatric patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Morton RE, Gray N, Vloeberghs M (2011) Controlled study of the effects of continuous intrathecal baclofen infusion in non-ambulant children with cerebral palsy. Dev Med Child Neurol 53(8):736–741

    Article  PubMed  Google Scholar 

  2. Takaomi T (2009) Intrathecal administration of GABA agonists in the vegetative state. Prog Brain Res 177:317–328

    Article  Google Scholar 

  3. Posteraro F, Calandriello B, Galli R, Logi F, Iardella L, Bordi L (2013) Timing of intrathecal baclofen therapy in persons with acquired brain injury: influence on outcome. Brain Inj 27(13–14):1671–1675

    Article  PubMed  Google Scholar 

  4. Ramstad K, Jahnsen R, Lofterod B, Skjeldal OH (2010) Continuous intrathecal baclofen therapy in children with cerebral palsy—when does improvement emerge? Acta Paediatr 99(11):1661–1665

    Article  CAS  PubMed  Google Scholar 

  5. Albright AL, Ferson SS (2009) Intraventricular baclofen for dystonia: techniques and outcomes. Clinical article. J Neurosurg Pediatr 3(1):11–14

    Article  PubMed  Google Scholar 

  6. Bonouvrié LA, Becher JG, Vles JS, Boeschoten K, Soudant D, de Groot V, van Ouwerkerk WJ, Strijers R, Foncke E, Geytenbeek J, van de Ven PM, Teernstra O, Vermeulen RJ (2013) Intrathecal baclofen treatment in dystonic cerebral palsy: a randomized clinical trial: the IDYS trial. BMC Pediatr 13:175

    Article  PubMed Central  PubMed  Google Scholar 

  7. FDA/Center for Drug Evaluation and Research (2014) Label and approval history: lioresal, NDA 020075. In: U.S. Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed 25 September 2014

  8. Ridley B, Rawlins RK (2006) Intrathecal baclofen therapy: ten steps toward best practice. J Neurosci Nurs 38(2):72–82

    Article  PubMed  Google Scholar 

  9. Secretariat MA (2005) Intrathecal baclofen pump for spasticity: an evidence-based analysis. Ont Health Technol Assess Ser 5(7):1–93

    Google Scholar 

  10. Francisco GE, Hu MM, Boake C, Ivanhoe CB (2005) Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury. Brain Inj 19(5):359–364

    Article  CAS  PubMed  Google Scholar 

  11. Hoving MA, van Raak EP, Spincemaille GH, Palmans LJ, Becher JG, Vles JS, Dutch Study Group on Child Spasticity (2009) Efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy: a randomised controlled trial. Eur J Paediatr Neurol 13(3):240–246

    Article  Google Scholar 

  12. Guglielmino A, Sorbello M, Fazzio S, Zingale SF, Bucolo GE, Pittalà G, Castiglione A, Patti F, Mangiameli S (2006) Continuous intrathecal baclofen administration by a fully implantable electronic pump for severe spasticity treatment: our experience. Minerva Anestesiol 72(10):807–820

    CAS  PubMed  Google Scholar 

  13. Dario A, Scamoni C, Bono G, Ghezzi A, Zaffaroni M (2001) Functional improvement in patients with severe spinal spasticity treated with chronic intrathecal baclofen infusion. Funct Neurol 16(4):311–315

    CAS  PubMed  Google Scholar 

  14. Pidcock FS (2007) Spasticity management. In: Transverse Myelitis Association. http://myelitis.org/symptoms-conditions/spasticity/spasticity-management/. Accessed 13 October 2014

  15. Snoek G, Fleuren J, Hermens H, Nene A, Rietman H, Witteveen H, Dekkers M, Broeze J, Lenders M, Dijkstra C (2010) Treatment algorithm for spasticity in adults. In: Institute for Research in Rehabilitation Medicine and Technology. http://www.simferweb.net/index.php?option=com_phocadownload&view=category&download=13:5-treatment-algorithm-of-spasticity-g-snoek-the-netherlands&id=3:topic-2-prm-and-people-with-spasticity. Accessed 13 October 2014

  16. Albright AL, Barry MJ, Shafron DH, Ferson SS (2001) Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 43:652–657

    Article  CAS  PubMed  Google Scholar 

  17. Gooch JL, Oberg WA, Grams B, Ward LA, Walker ML (2004) Care provider assessment of intrathecal baclofen in children. Dev Med Child Neurol 46(8):548–552

    Article  PubMed  Google Scholar 

  18. Coffey RJ, Edgar TS, Francisco GE, Graziani V, Meythaler JM, Ridgely PM, Sadiq SA, Turner MS (2002) Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehab 83(6):735–741

    Article  Google Scholar 

  19. Graham LA (2013) Management of spasticity revisited. Age Ageing 42(4):435–441

    Article  PubMed  Google Scholar 

  20. Bethoux F, Boulis N, McClelland S 3rd, Willis MA, Hussain M, Machado A, Mychkovsky L, Stough D, Sutliff M, Pioro EP (2013) Use of intrathecal baclofen for treatment of severe spasticity in selected patients with motor neuron disease. Neurorehabil Neural Repair 27(9):828–833

    Article  PubMed  Google Scholar 

  21. Ali D, Raad J (2014) Rehab measures: functional independence measure. In: rehabilitation Measures Database. http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=889. Accessed 3 July 2014

  22. Albright AL, Gilmartin R, Swift D, Krach LE, Ivanhoe CB, McLaughlin JF (2003) Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg 98(2):291–295

    Article  CAS  PubMed  Google Scholar 

  23. Mathur SN, Chu SK, McCormick Z, Chang Chien GC, Marciniak CM (2014) Long-term intrathecal baclofen: outcomes after more than 10 years of treatment. Am J Phys Med Rehab 6(6):506–513.e1

    Google Scholar 

  24. Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J (1993) Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 270(20):2475–2477

    Article  CAS  PubMed  Google Scholar 

  25. Albright AL (1996) Intrathecal baclofen in cerebral palsy movement disorders. J Child Neurol 1:S29–S35

    Google Scholar 

  26. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, Kroin JS (1989) Intrathecal baclofen for severe spinal spasticity. N Engl J Med 320:1517–1521

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors report no conflict of interest concerning the materials or methods used in this study or the finding specified in this paper.

Author information

Authors and Affiliations

  1. Goryeb Children’s Hospital at Morristown Medical Center, 100 Madison Ave., Morristown, NJ, 07960, USA

    Casey Melissa Berman, Melissa Ann Eppinger & Catherine Anne Mazzola

Authors
  1. Casey Melissa Berman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melissa Ann Eppinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catherine Anne Mazzola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Casey Melissa Berman.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berman, C.M., Eppinger, M.A. & Mazzola, C.A. Understanding the reasons for delayed referral for intrathecal baclofen therapy in pediatric patients with severe spasticity. Childs Nerv Syst 31, 405–413 (2015). https://doi.org/10.1007/s00381-014-2591-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-014-2591-4

Keywords

Search

Navigation